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“Half of the secrets of the cell are outside the cell.”  
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Abstract 
Microglia are the innate immune cells of the brain. One of the main characteristics of 
microglia is its extremely plasticity, which is necessary for them to deal with changing 
circumstances. Activation of microglia can contribute to contrasting effects by either pro-
inflammatory, anti-inflammatory, or tumor-supportive phenotypes. Adult and pediatric high-
grade glioma are very aggressive tumors with a median survival of less than a year. The 
pathological hallmark of these tumors is the invasion into brain tissue, which contributes 
significantly to the failure of current therapeutic treatments. Glioma cancer recruits microglia 
for their expansion and invasiveness. During the course of the disease, glioma-infiltrating 
microglia undergo cellular reprogramming and functional changes that are controlled by 
specific intracellular signaling pathways and epigenetic mechanisms. 
In the first study, we describe a novel epigenetic pathway associated with microglia 
reprogramming toward the tumor-supporting phenotype that is of benefit to glioma biology. 
We demonstrate that the glioma-induced microglia tumor-supporting phenotype is coupled 
with a functional interaction between sirtuin 1 (SIRT1) and the specific H4K16 histone 
acetyltransferase hMOF, which leads to an increase of the global histone 4 lysine 16 (H4K16) 
acetylation. During the process of microglia reprogramming toward the tumor-supporting 
phenotype, we show that SIRT1 deacetylates hMOF that promotes its recruitment to the 
chromatin and enhances its enzymatic activity against H4K16 acetylation. The high 
enrichment in H4K16 acetylation results in an aberrant gene expression in tumor-supporting 
microglia. Furthermore, we show that the manipulation of H4K16’s acetylation level, 
controlled by the enzymes hMOF and SIRT1, has an impact on microglial pro-tumoral 
activation.  
Diffuse intrinsic pontine glioma (DIPG) is a pediatric high-grade glioma (pHGGs) that 
carries H3K27M mutation and has a reduced global level of the repressive posttranslational 
histone modification H3K27me3. In the second study, we explore the microglia profile in 
pHGGs and DIPG. Our research work suggests that microglia activation towards a tumor-
supporting phenotype exhibits a significantly decreased level of H3K27me3 and demethylase 
JMJD3. Interestingly, the inhibition of EZH2 or JMJD3/UTX enzymes reduces the switch of 
microglia into pro-tumoral phenotype, which in turn has a negative effect on DIPG and 
pHGGS invasion.   
In the third study, we thoroughly describe a completely novel molecular mechanism used by 
glioma cells to transform microglia into a tumor-supporting phenotype. We demonstrate in 
vitro and in vivo that decreased basal caspase-3 activity in microglia is a necessary condition 
for their polarization into a tumor-supportive phenotype. We reveal that nitric oxide 
originating from the glioma’s nitric oxide synthase-2 induces the inhibition of microglial 
thioredoxin-2 denitrosylation activity, which in turn leads to an increased S-nitrosylation of 
caspase-3. 
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1. INTRODUCTION 
1.1 GLIOMA 
The central nervous system (CNS) is composed of the brain and the spinal cord. The brain is 
populated by different cell types that can be classified into neuronal and glial cells. Glial cells 
are further classified into astrocytes, oligodendrocytes and microglia, which are involved in 
maintaining the brain’s homeostasis. The brain is an organ isolated from the peripheral 
immune system due to the presence of the blood brain barrier (BBB) and the absence of 
lymphatic vessels. Under certain conditions such as inflammation, the BBB becomes 
impaired and permeable to monocytes and other immune cells, and may allow larger 
molecules to enter the brain (Ballabh et al. 2004). 
Brain tumors are characterized by high morbidity and mortality. They are classified into 
primary central nervous system tumors and secondary metastatic brain tumors that are 
derived mostly from lung and breast cancer. Primary brain tumors are a heterogeneous group 
of tumors arising from cells within the brain parenchyma and meninges.  
Glioma is the most common malignant primary CNS tumor and remains the most difficult 
cancer to treat. Indeed, gliomas arise from the neuroglial stem or progenitor cells and are 
responsible for the majority of deaths from primary brain tumors. They account for 28% of 
all brain tumors and 80% of malignant tumors (Weller et al. 2015). 
A glioma is diagnosed with an MRI upon development of symptoms such as seizures and 
focal neurological deficits. Diagnosis is based on histological classification of the tumors and 
by the World Health Organization (WHO) grading of malignancy from low to high, grade I 
to IV. In adults, gliomas include pilocytic astrocytomas, pleomorphic xanthoastrocytomas, 
and ependymomas that are less common and have a better prognosis. Moreover, Gliomas, 
that occur most frequently, include oligodendrogliomas and the controversial group of mixed 
oligoastrocytomas as well as infiltrative astrocytomas of various grades such as diffuse 
astrocytoma (WHO grade II), anaplastic astrocytoma (WHO grade III), and glioblastoma 
(WHO grade IV) (Louis et al. 2007). In young adults, pilocytic astrocytomas and diffuse 
midline gliomas such as diffuse intrinsic pontine gliomas of various grades are the most 
common types (Table 1). 
The WHO classification, updated in 2016, is based on genetic alterations combined with 
histology. According to the 2016 WHO classification, gliomas are grouped into 
circumscribed gliomas and diffusely infiltrating gliomas, depending on their proliferation and 
genetic landscape (DeWitt et al. 2017). Gliomagenesis is accompanied by genetic alteration, 
chromosome instability, and unregulated growth factor signaling pathways. Also, Genome 
sequencing uncovered aberrant epigenomes characterized by altered DNA methylation and 
histone modifications that are present across several adult and pediatric brain tumors. 
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Table 1. Gliomas classification 
 
1.1.1 Glioblastoma Multiform 
Glioblastoma multiform (GBM) is the most common and aggressive malignant de novo 
primary brain tumor. GBMs occur mostly in patients over 50 years old, however, they can 
also be manifested in children and young adults. The latter is genetically different from adult 
glioblastoma. Molecular profiling has improved on the understanding of glioma pathogenesis. 
Using a comprehensive approach, diffuse gliomas are grouped based on their IDH (Isocitrate 
dehydrogenase) mutation profile (Table 2) (Lapointe et al. 2018; Chen et al. 2017a; Yan et 
al. 2009). There are two forms of IDH: cytosolic IDH1 and mitochondrial IDH2. IDH1/2 
convert isocitrate to a-Ketoglutarate (a-KG), coupled with reduction of NADP+. However, in 
IDH1/2 mutant glioma, a-KG is catalyzed to R(-)-2-hydroxyglutarate (2-HG) in a NADPH-
dependent manner, thereby causing oxidative stress, histone methylation, and hyper-
methylation of several CpG islands that are linked to a better prognosis in this type of tumor. 
Most glioblastoma that occur in patients over 50 years old represent two distinct subgroups: 
the mesenchymal and the receptor tyrosine kinase (RTK) classes (Stommel et al. 2007). The 
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latter is characterized by higher amplification of the growth factor receptor (EGFR) and its 
active variant III (EGFRv III), which in turn promotes the tumor growth (Brennan et al. 
2013). This feature makes EGFR a good target for immunotherapy. Moreover, a high level of 
the DNA repair protein O6-methylghuanine DNA methyltransferase (MGMT) in 
glioblastoma leads to temozolomide treatment resistance (Melguizo et al. 2012). Therefore, 
hyper-methylation of a CpG-rich region of MGMT promoter inhibits DNA repair in tumor 
cells treated with alkylating chemotherapies, which will be of benefit for glioblastoma 
patients (Esteller et al. 2000; Hegi et al. 2005). 
 
 
 
 
 
 
Table 2. Diffuse gliomas grade VI subgroups 
 
1.1.2 Diffuse Intrisic Pontine Glioma 
Brainstem gliomas represent 10–20% of pediatric brain tumors (Monje et al. 2011). They are 
clustered into diffuse intrinsic pontine gliomas (DIPG) that arise mainly in the ventral pons, 
and low-grade gliomas, which occur in the dorsal pons or midbrain. DIPG are extremely 
infiltrative and aggressive as compared to the low-grade ones that have a markedly better 
survival course (Wong et al. 1999; Buckner 2003). Notably, the compact structure of the 
brainstem is a major limitation in the penetration of the BBB in DIPG treatment. Thus, 
irradiation combined with chemo-radio therapy remain the standard treatment for DIPG 
(Gwak and Park 2017).  
Childhood brain tumors can carry mutations in the genes, encoding the histone 3 variants 
H3.3 (H3F3A) and H3.1 (HIST1H3B and HIST1H3C), which lead respectively to the 
substitution of lysine (K) to methionine (M) at position 27 in the histone 3 tail (H3K27M) 
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and the subsequent glycine to arginine or valine at position 34 (G34R/V) (Jones et al. 2017). 
These mutations have not yet been found in elderly patients with glioblastoma.  
Clinical diagnosis reveals that DIPGs have a very bad prognosis and they are specific and 
distinct from other high-grade gliomas. Furthermore, H3K27M mutation represents a major 
hallmark of DIPG tumors that drives DNA hypo-methylation and reduced trimethylation of 
histone H3 at lysine 27 (H3K27me3) are major hallmark of DIPG tumors (Chan et al. 2013).  
It has been reported that H3K27M mutation drives DIPG oncogenesis by repressing the 
catalytic activity of the polycomb repressive group (PRC2) due to an increased binding 
affinity of the mutant histone to the PRC2 catalytic subunit, EZH2 (Mohammad et al. 2017). 
In counterpart, according to another study, EZH2 and its enzymatic product H3K27me3 are 
not recruited in chromatin sites enriched with H3K27M (Piunti et al. 2017). Therefore, the 
functional outcome of H3K27M remains incomplete and further investigations could advance 
our understanding of epigenetic mechanisms required for DIPG proliferation.  
Advances in molecular biology have defined a new era in the epigenetic field, which holds 
promise for possible therapies of DIPG (Hashizume 2017). Different immune therapies for 
DIPG are being explored, including tumor vaccine strategies and the blockade of 
programmed cell death protein 1 (PD-1). Furthermore, pharmacological inhibition of the 
histone demethylase Jumonji domain containing 3 (JMJD3) or the methyltransferase 
enhancer of zeste homolog 2 (EZH2) reduces tumor growth and invasion in DIPG 
(Hashizume et al. 2014; Ridler 2017; Mohammad et al. 2017).  
 
1.1.3 Glioma Models 
Several laboratories use in vitro drug testing in order to develop potential targeted therapies 
for DIPG and glioblastoma. Usually, glioma cells are cultured as a monolayer with fetal 
bovine serum (FBS), but recently, neurospheres derived from the three-dimensional serum-
free cell culture represent a powerful tool for in vitro drug screening. These neurospheres 
mimic the original tumor better because they are enriched with brain tumor stem cells 
(BTSC). 
Gliomas were extensively studied in the cell culture system; however, this approach is not 
good enough to model the complexity of the in vivo tumor microenvironment as well as the 
angiogenesis and metastasis. Therefore, several approaches have been used to generate the 
glioma animal model.  Glioma models were chemically induced by DNA alkylating agents 
and used to establish cell lines such as C6, 9L, and GL261 (Stylli et al. 2015). These 
established cell lines were transplanted into a syngeneic immunocompetent mouse in order to 
study the cross-talk between the tumor and its microenvironment (Benda et al. 1968) 
(Huszthy et al. 2012).  
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Similar to glioblastoma, DIPG rodent models are generated through the intracranial injection 
of rat glioma cell lines such as F98, 9L, and C6 into the brainstem of immunocompromised 
neonatal rats, leading to the formation of brainstem tumors. The human glioma xenograft 
models are established by the transplantation of cultured human monolayer cell lines that are 
derived from biopsy material (Shapiro et al. 1979). Human DIPG xenograft models are 
established by direct inoculation of either dissociated neurospheres or patient-derived DIPG 
cells in order to develop pontine DIPG-like tumors (Misuraca et al. 2016). The xenograft 
model is very useful to validate preclinical studies (Horten et al. 1981).    
Genetically engineered immunocompetent mouse models also exist, and are very convenient 
to understand glioma development. These models are generated by specific genomic 
manipulation that can be either transgenic or loss of function (Fomchenko and Holland 2006). 
 
1.1.4 Tumor Microenvironment in Glioma 
Cancer research has been focused on neoplastic cells for many decades, but their influence on 
the tumor microenvironment has not had the same level of attention. Interactions between 
cancer cells and their stroma is vital and may disrupt the surveillance of the immune system 
for tumor survival and progression. The interaction between the microenvironment and the 
cancer cell was first proposed by a 19th century English surgeon, Stephen Paget, with his 
“seed and soil” hypothesis. He argued that cancer cells (“the seeds”) selectively metastasize 
to neoplastic-promoting niches (“soil”) (Langley and Fidler 2011; 2018). After “seeding”, 
cancer cells actively corrupt their microenvironment by releasing growth factors, chemo-
attractants, and cytokines. The tumor microenvironment is also clinically relevant, as it can 
affect patient prognosis and potentially confer drug resistance, resulting in potential relapse 
and metastasis. 
A dynamic cellular microenvironment shapes and supports a glioma tumor. Indeed, glioma-
secreted factors like cytokines and chemokines in order to attract and recruit astrocytes, 
pericytes, endothelial cells, and immune cells such as brain-resident microglia, peripheral 
macrophages, T cells, and myeloid-derived suppressor cells (MDSCs), which will maintain 
an immunosuppressive microenvironment (Gabrilovich et al.). Of note, the presence of 
infiltrating T cells and MDSCs in the glioma supports the hypothesis of a leaky BBB (Davies 
2002; Jain et al. 2007). MDSCs in glioma are a heterogeneous population of immature 
precursor cells of macrophages, dendritic cells, and granulocytes (Gielen et al. 2015).These 
cells inhibit cytotoxic activity of natural killer cells and suppress adaptive immune response 
by promoting CD4+ or CD8+ T cell apoptosis. However, MDSC induces regulatory T cell 
(Treg) response, which is a potent inhibitor of effector T cells (Marvel and Gabrilovich 
2015). In addition, glioma secrete B7-H1, TGF-b and interleukin 10(IL10) to inhibit anti-
tumor T cell activation (Figure 1) (Wintterle et al. 2003; Perng and Lim 2015). 
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Glioma-associated microglia and macrophages are the predominant population in malignant 
gliomas. In brain tumors, bone marrow-derived macrophages exert the same role as microglia 
in promoting glioma progression (Gieryng et al. 2017b). Yet, the question remains about how 
to distinguish between microglia and infiltrating macrophages in glioma. The expression 
level of CD45 is commonly used to identify microglia (CD45low) from tumor-associated 
macrophages (CD45high) by flow cytometry in in vivo models of glioma tumors. However, it 
has been found that microglia are able to upregulate CD45 expression; thus, this marker does 
not accurately discriminate microglia and bone marrow-derived monocytes in human samples 
(Müller et al. 2015; Chen et al. 2017b). Recently, putative markers such as SALL1 and 
TMEM19 has been identified to separate microglia from peripherally derived macrophages in 
murine glioma models, (Bennett et al. 2016).  
On the other hand, microglia and macrophages, infiltrating the tumor microenvironment of 
DIPG, are less inflammatory as compared to adult GBM. Also, lack of infiltrating 
lymphocytes leads to ineffective adaptive immune response in DIPG tumors (Lin et al. 2018). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Illustration of the immune response in glioma microenvironment. 
Adapted from (Gieryng et al. 2017b) 
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1.2 MICROGLIA 
Microglia are the resident myeloid cells of the CNS. They constitute 10–20% of the non-
neuronal cell population in the brain. Historically, microglia were first stained and 
characterized by Franz Nissl in 1880, and eventually termed microglia by Río-Hortega in 
1919 (Ginhoux et al. 2013). They continually survey the brain and respond rapidly to stimuli 
and threats in their microenvironment. Indeed, they express surface receptors to detect 
changes due to brain damage or infections and migrate to the site of injury. Microglia are 
necessary for brain homeostasis, indeed, they have direct contact with other glia cells and 
neurons during brain development and neurogenesis. Several studies have been conducted in 
the last two decades to better understand the functional role of microglia in development, 
neurodegenerative diseases, and brain tumors. These innate immune cells of the brain can 
contribute to rather contrasting effect, promoting neuronal cell death or tumor cell 
progression. Their vital role in pathological events makes them a potential therapeutic target. 
 
1.2.1 Microglia Ontogeny and Homeostasis 
The origin of microglia has long been debated. They were first described as derived from 
hematopoietic stem cells in the bone marrow (Ginhoux et al. 2013). Notably, recent 
fluorescence-activated cell sorting approaches in mice have identified that microglia cells 
originate from myeloid progenitors in the yolk sac. They are CD45low and they express the 
transcription factor RUNX1 and the receptor tyrosine kinase c-Kit, also named CD117 during 
embryogenesis (Kierdorf and Prinz ; Salter and Stevens 2017). These pre-microglia migrate 
to the CNS via the circulatory system during development between day E8.5 and E9.5 before 
the establishment of the BBB. In the brain, microglia cells undergo different developmental 
steps, where they proliferate and acquire their ramified morphology. In the case of brain 
disease, the BBB is disrupted and other peripheral monocytes migrate and undergo 
differentiation in reaction to inflammation.   
Since the microglia cell population arises during early embryogenesis, the adult microglial 
pool is able to renew itself in the CNS without the contribution of circulating monocytes. 
This finding has been supported in mice by bone marrow (BM) irradiation, chimerism (Ajami 
et al. 2007; Mildner et al. 2007), and cell lineage-tracing  (Ginhoux et al. 2010). However, 
under pathological conditions, blood-derived and bone marrow-derived monocytes infiltrate 
and colonize the brain transiently and differentiate into cells that are phenotypically very 
similar to resident microglia (Ajami et al. 2011). Notably, CD45 antibody has been used 
intensively to distinguish microglia from macrophages. However, because microglia are able 
to upregulate CD45 expression in human glioma samples, CD45 does not accurately 
discriminate microglia and bone marrow-derived monocytes (Badie and Schartner 2000). 
This concept was supported by using irradiation chimeras with a protected head. This study 
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shows that most tumor associated macrophage/microglia (TAM) are actually intrinsic 
microglia (Müller et al. 2015). 
The microglial population is different from other CNS cells and is considered the 
macrophages of the brain. Of note, gene expression and transcriptome profiling reveals 
distinct gene expression signatures of inactivated microglia compared to peripheral myeloid 
cells as well as other CNS cells (Mammana et al. 2018).  
Balanced microglia development and proliferation depend on several molecular pathways. 
The myeloid transcription factor PU.1 is important for microglia development in the yolk sac. 
Its absence results in reduction of microglia density (Kierdorf et al. 2013). In addition, 
colony-stimulating factor 1 (CSF-1) is essential to maintain microglia homeostasis. 
Deficiency of CSF-1 or the ligand Interleukin 34 (IL34) leads to significant loss of microglia 
in embryonic and adult mouse brains (Askew et al. 2017).   
 
1.2.2  Microglia Role within the CNS 
Microglia have been extensively studied for their role in immunity and neurological disorders 
such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) as well as in tumor biology. 
Furthermore, there is strong evidence that highlights the important role of microglia during 
brain development. Microglia instruct the functions that are crucial for a healthy CNS, 
exemplified by programmed cell death and clearance of apoptotic newborn neurons, as well 
as pruning developing axons and synapses. Later in adulthood, they are responsible for 
regulating neuronal and synaptic plasticity. In rodent models, microglia can be stimulated 
through ATP release in their local environment, which is mediated by glutamate-receptor 
agonists. Interestingly, phagocytic microglia clean up the brain from accumulated apoptotic 
neurons that express “eat me” signals, like phosphatidylserine (PS) which recognized directly 
by microglial receptor the milk fat globule epidermal growth factor 8 (MFG-E8) (Hanayama 
et al. 2002).  
Besides clearance of apoptotic cells, microglia promote neurogenesis and axonal wiring by 
producing neurotrophic factors, including the insulin-like growth factor 1(IGF-1) signaling 
pathway (Ueno et al. 2013) as well as Interleukin 1 beta (IL-1b) and the interferon gamma 
(IFN-g) in the subventricular zone (Shigemoto-Mogami et al. 2014). They, also, regulate the 
number of neuronal precursor cells (NPCs) and in particular, Cunningham and colleagues 
demonstrate that the microglia activation state affects NPC survival (Cunningham et al. 
2013). Indeed, microglia regulate synaptic circuits during early and late postnatal stages. In 
addition, they mediate synaptic pruning by removing unwanted synapses and promoting the 
generation of new ones (Wake et al. 2009; Paolicelli et al. 2011; Schafer et al. 2012; 
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Tremblay et al. 2010). Therefore, microglia functions in this context depend on the molecular 
signaling pathway and biological state. 
1.2.3 Microglia Plasticity  
Microglia are multitasking cells that survey brain function, under physiological and 
pathological conditions. They are very plastic and constitute a group of cells with diverse 
morphologies and biological activities, rather than a uniform cell population (Nimmerjahn et 
al. 2005). The cross-talk between microglia and their microenvironment results in change in 
microglia phenotype form ramified to amoeboid (Tam and Ma 2014) and accompanied by 
polarization to specialized functions in response to environmental cues (Hanisch 2002). 
Based on macrophage classification, the best characterized microglia activation phenotypes 
are the classical M1 or the alternative M2 activation. Microglia are activated toward the M1 
phenotype in response to pathogens and is induced by interferon g (IFN-g) or 
lipopolysaccharides (LPS), resulting in the release of different inflammatory mediators like 
interleukines IL-1b, IL6, and nitric oxide (NO). Contrarily, upon stimulation of IL4 or IL13, 
microglia polarize toward the M2 phenotype, which is characterized by production of anti-
inflammatory cytokines and arginase 1(Arg1), which is needed for tissue remodeling.   
Advances in new technologies have defined a limitation of the M1/M2 classification concept 
for microglia/macrophage polarization that doesn’t reflect the complexity of microglia/ 
macrophage activation and functions (Ransohoff 2016). Indeed, according to a recent study, 
tumor-associated microglia cannot be characterized by the M2 phenotype and its subtypes 
(Nayak et al. 2014; Szulzewsky et al. 2015).  
Improved isolation method of microglia combined with genome-wide transcription analysis 
and chromatin sequencing approaches revealed that microglia harbor different transcription 
and epigenetic signatures depending of their specific functions which confirm that their role 
and location will shape their chromatin and genome. It is known that epigenetic patterns play 
crucial role in stem cell reprogramming and cellular differentiation. Like stem cells, microglia 
are very sensitive to changes in their microenvironment and they undergo cellular 
reprogramming in order to differentiate toward various phenotypes and fulfill their role in 
normal brain, but also in the context of diseases (Cheray and Joseph 2018). Thus, microglia 
cells acquire specific chromatin modifications to obtain their unique molecular signature and 
plasticity   
Consequently, microglia polarization is a dynamic and complex process that depends on 
activation of different intracellular signaling pathways (Li and Graeber 2012; Nayak et al. 
2014). There is strong evidence that microglia identity and activation is mainly the result of 
changes in gene expression patterns that rely on the transcriptional factor network and the 
chromatin landscape (Figure 2) (Boche et al. 2013; Sousa et al. 2018). Thus, it is important 
to identify molecular and epigenetic mechanisms that underlie microglia plasticity. 
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Figure 2. Microglia plasticity is associated with transcription and epigenetic changes. 
Adapted and modified from (Cheray and Joseph 2018) 
 
1.2.4 Tumor-Associated Microglia  
Glioma cells release soluble factors, including granulocyte-macrophage colony-stimulating 
factor (GM-CSF), which attract microglia in large numbers as the absence of GM-CSF 
decreases microglia invasion in organotypic brain slices and reduces intracranial glioma 
growth in vivo (Sielska et al. 2013). Hence, microglia density correlates with the malignancy 
of the glioma. Tumor associated microglia play an active part in promoting the invasive and 
proliferative features of glioblastoma. In fact, the pro-inflammatory cells switch to 
immunosuppressive microglia cells in the course of glioblastoma (Wei et al. 2013).  
Glioma cells recruit and exploit microglia for their expansion. It has been reported that 
microglia cells and microglia secreted factors contribute to GL261 gliomas motility, however, 
endothelial cells and oligodendroglia have a moderate effect on glioma migration ability 
(Bettinger et al. 2002). In a similar study, deletion of endogenous microglia by treating 
organotypic brain slice cultures with liposomes carrying clodronate, results in reduced glioma 
invasiveness (Markovic et al. 2005). 
Indeed, glioma attract microglia via monocyte chemoattractant protein-1 (MCP-1), also 
known as CCL2. Thereafter, glioma stimulates the release of IL6 from microglia by acting on 
the CCL2 receptor named CCR2 of microglia, which in turn promotes glioma invasiveness 
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(Saederup et al. 2010; Zhang et al. 2012). In addition, microglia promote glioma proliferation 
and invasion through activation of matrix metalloproteases (MMPs) as well as the release of 
epidermal growth factor (EGF) (Coniglio et al. 2012). For instance, overexpression of TGF-β 
in microglia will activate pro-MMP2 production in gliomas. Subsequently, gliomas release a 
chondroitin-sulfate proteoglycan named versican, which triggers the release of MMP9 and 
MMP14 (MT1-MMP) from microglia cells by activating microglial TLR2 and p38-MAP-
kinase signaling. MMP14 cleaves pro-MMP2 produced by glioma into active MMP2, leading 
to degradation of the extracellular matrix (ECM) (Figure 3) (Markovic et al. 2009). Glioma 
stem cells (GSCs) use periostin (POSTN), also known as osteoblast-specific factor ECM 
protein, to attract microglia through the integrin receptor αvβ3. A report demonstrated that 
released factors from GSCs reduce microglia phagocytosis and stimulate the production of 
IL10 and TGF-β in microglial cells (Wu et al. 2010). However, it has been reported that naïve 
microglia can reduce tumor growth by inhibiting GSC sphere formation (Sarkar et al. 2013).  
It is clear that microglia exhibit a considerable degree of plasticity in the glioma 
microenvironment, where gliomas are considered to drive microglia cellular reprogramming 
through chromatin modifications mediated by epigenetic regulators. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Microglia glioma cross-talk
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1.3 EPIGENETICS 
Epigenetics refers to modifications in gene expression without alterations in the genetic code 
(Berger et al. 2009). The epigenetic landscape is established during embryogenesis and 
defines the cell identity even after division. It helps us to better understand cell fate decision 
and the functional outcome to subsequent stimuli. Therefore, epigenetic signatures are 
considered traditionally stable and are mediated by posttranslational modifications of histone 
and DNA-binding proteins as well as by hydroxyl-methylation of CpG DNA motifs, 
nucleosome remodeling, and noncoding RNA (Bird 2007). Recently, it has become clear that 
these modifications can change within a matter of minutes in response to polarization stimuli 
and will define the chromatin accessibility for protein binding, such as signaling transcription 
factors and their localization in the genome. 
Epigenetic modifications are considered a potential driver or inhibitor of tumor growth that is 
dramatically dictated by signaling alteration in their microenvironment (Mack et al. 2015). 
Similarly, they play an important role in sculpting the specificity of microglia polarization in 
response to different stimuli and is crucial for initial activation (Cheray and Joseph 2018).  
 
1.3.1 Chromatin Architecture and Histone Modifications 
In eukaryotic cells, the histone octamer consists of two units of the four core histone proteins 
H2A, H2B, H3, and H4. The positive charge given to the histone tail by the lysine assures the 
packaging of the long DNA molecules by opposing its negative charge. Originally, histones 
were considered as a static scaffold for DNA packaging (Luger et al. 1997). Indeed, they are 
able to wrap 147 base pair units of double-stranded DNA, forming a compact unit known as 
nucleosomes. 
Histones were shown to be dynamic proteins undergoing posttranslational modification, 
involving phosphorylation, ubiquitination, methylation, and acetylation, which are written 
and erased by histone modifier enzymes. For instance, modification of the histone amino acid 
residues dictates the histone code pattern recognized by histone readers and will facilitate the 
recruitment of transcriptional coactivators or corepressors. A key concept is that chromatin 
accessibility can be remodeled by the balance between the repressive and positive histone 
modifications. Consequently, chromatin can condense, leading to transcriptional repression, 
or can be open for transcription-factors binding, which will promote gene expression 
(Cosgrove et al. 2004). The functional implication of these modifications is complex and 
depends on which residue they are located in the gene locus [the promoter or the gene body] 
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(Schneider and Grosschedl 2007). Methylation and acetylation of histones are the 
predominant epigenetic modifications. Histone methylation can act as a transcriptional 
repressor or activator. Histone residues are methylated by histone methyltransferases (HMTs) 
and demethylated by histone demethylases (HDMs). Besides, histones are acetylated by 
histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (Allis 
et al. 2007). In particular, lysine acetylation is associated with an open chromatin structure 
that promotes transcriptional activation (Figure 4) (Koch et al. 2007).  
For instance, histone acetylation regulates the kinetics of gene induction for inflammatory 
response. Concordantly, it has been shown that HDAC inhibitors repress induction of various 
inflammatory genes (Blanchard et al. 2002) and have been used intensively to reduce LPS-
induced microglia inflammatory activation in vitro (Durham et al. 2017). Likewise, a low 
level of histone acetylation, such as acetylation of lysine 9 on histone H3 (H3K9ac) correlates 
with reduced efficiency in induced reprogramming of nuclei from fibroblast, and HDACs 
inhibitors can improve the reprogramming efficiency (Hezroni et al. 2011). 
 
1.3.2 Histone H4 Lysine 16 Acetylation 
H4K16 acetylation plays an important role in transcriptional activation and modulation of 
chromatin structure. It is mainly regulated by the opposing effect of the HAT 
KAT8/MYST1/hMOF (human orthologue of the Drosophila melanogaster gene males absent 
on the first) and the NAD – dependent HDAC Sirtuin 1 (SIRT1). 
The amount of H4K16ac in the nucleus depends on the cell type and environmental cues 
(Horikoshi et al. 2013). For instance, accumulation of H4K16 acetylation close to the 
transcriptional start site (TSS) of a specific gene will displace the nucleosome, resulting in an 
open chromatin structure, and acts as a binding platform for transcriptional factors and RNA 
polymerase complex in order to initiate the transcription (Schones et al. 2008). Alteration in 
the mark H4K16ac could result in genomic instability and aberrant gene expression (Li et al. 
2010; Fullgrabe et al. 2011). Therefore, deregulation of this specific modification is linked to 
various diseases, including cancer (Gorisch et al. 2005; Hajji et al. 2010). 
MOF is an acetyltransferase highly conserved among eukaryotes, and is a member of the 
MYST family (from the founding members: MOZ, Ybf2 / Sas3, Sas2, and Tip60). It was first 
identified in Drosophila, and is one of the key components of the dosage compensation 
complex or MSL (male specific lethal complex), which is required to balance gene 
expression between the sexes (Rea et al. 2007). 
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1.3.3 H4K16ac Remodelers 
MOF is of particular interest as it displays quite diverse roles in various nuclear processes. It 
is responsible for acetylating H4K16 and non-histone proteins. Indeed, it is implicated in 
transcriptional regulation as well as in DNA damage, DNA repair, and cell growth by 
activating the protein kinase ATM (ataxia – telangiectasia mutated) and apoptosis by 
acetylating p53 (Mellert and McMahon 2009; Lu et al. 2011). 
Most HATs target different types of histone residues; however, hMOF enzymatic activity has 
an extraordinary specificity for K16 at histone H4. Moreover, hMOF knockdown results in 
decrease or complete loss of H4K16ac. Therefore, any process mediated through H4K16ac 
can potentially be influenced by hMOF. Recent observations suggest that hMOF and 
H4K16ac may be involved in tumorgenesis (Rea et al. 2007; Zhao et al. 2013).  
Sirtuins are highly evolutionarily conserved enzymes, which were first discovered in 
Saccharomyces Cerevisiae and named silence information regulators (SIR2). There are seven 
SIR2 mammalian sirtuins, termed SIRT1 through SIRT7 (Donmez 2012). The human protein 
SIRT1 has different domains, including nuclear localization signals (NLS), nuclear export 
signals (NES), essential for SIRT1 activity, and an enzymatic core. Besides, SIRT1 
deacetylates both histones and non-histone proteins by hydrolyzing NAD+ and transferring 
the bounded acetyl group to an ADP- ribosyl group (Revollo and Li 2013). Indeed, hMOF 
autoacetylation changes the surface charge of the protein and alters its binding to the 
nucleosome. Thereby, SIRT1 deacetylates hMOF and promotes its recruitment on the 
chromatin leading to upregulation of H4K16ac (Lu et al. 2011). 
SIRT1 is highly expressed during embryogenesis and in the adult mouse brain. SIRT1 
participates in various cellular functions in distinct subcellular locations that may change 
during embryonic development and in response to biological stimuli (Hisahara et al. 2008). 
Therefore, its subcellular localization must affect its function. 
SIRT1 has been extensively investigated in cancer and neurodegeneration (Donmez 2012). 
Clearly, small molecule activators or inhibitors of SIRT1 can prevent or treat age-related 
diseases (Outeiro et al. 2008; Zhang et al. 2011). Remarkably, SIRT1 has protective effect in 
neuronal toxicity (Araki et al. 2004; Anekonda and Reddy 2006) and prevents toxicity of 
microglia-dependent plaque deposition of amyloid B (AB) in AD by inhibiting the nuclear 
factor NF-kB signaling. SIRT1 interacts with the RelA/P65 subunit of NF-KB and inhibits 
transcription by deacetylating RelA/P65 at lysine 310 (Gan and Mucke 2008; Yang et al. 
2012). Moreover, the SIRT1-p53-caspase 3-dependent apoptotic pathway is involved in PD. 
For instance, decrease of SIRT1 activity in microglia leads to high levels of TNF-a and IL6. 
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These microglia-derived factors will inhibit p53 deacetylation by reducing SIRT1 expression, 
and promote apoptosis in neurons (Ye et al. 2013). Collectively, H4K16ac and its regulators 
are implicated in various diseases, which may be potential targets for drug development.  
 
1.3.4 Histone H3 Lysine 27 Tri-methylation (H3K27me3) 
H3K27me3 is a hallmark of repressed transcription while acetylation of H3K27 is tightly 
associated with an active gene promoter (Tie et al. 2009). H3K27me3 is involved in complex 
biological processes, including cellular differentiation (Boyer et al. 2006; Bracken et al. 
2006) inactivation of chromosome X (Rougeulle et al. 2004), and disease development. 
Trimethylated H3K27 is studied more than the mono- and di-methylation of lysine 27 at H3. 
H3K27me2 has the same distribution as H3K27me3; they act in opposition to H3K27me1 
and H3K4me3 (Barski et al. 2007).  
Tri-methylation of H3K27 is catalyzed only by EZH2, which is the catalytic subunit of 
PRC2. The polycomb group (PcG) proteins are implicated in the silencing of Hox gene 
expression as identified first in Drosophila (Lewis, 1978). These proteins play a key role in 
the maintenance of cell-type identity, differentiation, and disease by establishing themselves 
in a repressive chromatin. There are two polycomb repressive complexes (PRC) known as 
PRC1 and PRC2.   
PRC2 binds to the chromatin and mediates H3K27 tri-methylation through its catalytic 
subunit, EZH2. H3K27me3 is then recognized by PRC1, leading to chromatin compaction 
and RNAPII pausing (Francis et al. 2004). EZH2 also acts as a binding platform for DNA 
methyltransferases at repressed promoters, thus linking histone methylation to DNA 
methylation (Vire et al. 2006). In various cancers, both PRC1 and EZH2 are upregulated 
(Aloia et al. 2013). 
The ubiquitously transcribed tetratricopeptide repeat X (UTX) and the Jumonji domain 
containing 3 (JMJD3 known also as KDM6B) were first described in 2007 as histone 
demethylases, which contain the Jumonji C (JmjC) catalytic domain (Agger et al. 2007). 
They have an antagonist function for the EZH2 that regulates the balance of H3K27me3 
level. Both enzymes are implicated in gene expression by maintaining an open chromatin 
state, and play a significant role in chromatin remodeling (Svotelis et al. 2011; Kooistra and 
Helin 2012). It has been demonstrated in macrophages using chromatin immunoprecipitation 
coupled with next generation sequencing (ChIP-Seq) data that the UTX/JMJD3 complex is 
enriched in H3K4me3 loci associated with active genes (De Santa et al. 2009). Alterations in 
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H3 lysine 27 demethylases lead to unbalanced gene expression. For instance, in mouse, loss 
of JMJD3 or UTX results in embryonic lethality. Moreover, JMJD3 and UTX are required 
for T cell subset development and neurogenesis (Arcipowski et al. 2016). JMJD3 and UTX 
have been intensively investigated for their critical functions in cellular reprogramming and 
cancer, and are considered potential therapeutic targets in many diseases (Agger et al. 2007; 
Ezponda et al. 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Post-translational modifications on histone tails. 
Adapted from (Cheray and Joseph 2018) 
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1.4 NITRIC OXIDE AND CASPASE 3  
Nitric oxide (NO) in mammalian cells is produced via conversion of L-arginine to L-citrulline 
by nitric oxide synthase (NOS) (Lee et al. 2005). NOS2, one of the three NOS isoforms, has a 
vital function in immune response and cancer. Therefore, it is induced by inflammatory 
stimuli like LPS and TNFa, causing the production of NO in large amounts. The NO 
signaling pathway mediates posttranslational modifications like S-nitrosylation of cysteine 
residues on proteins that are involved in cellular functions. Moreover, massive production of 
NO was also observed in several cancers, including high-grade glioma (Cobbs et al. 1995; 
Choudhari et al. 2013). Thus, NO can promote angiogenesis, invasion and tumor progression 
(Ying and Hofseth 2007). Highly conserved caspases (cysteine dependent aspartate directed 
proteases) are a family of proteases that cleave their substrate at aspartate residues. They are 
expressed as inactive pro-form (pro-caspase) that need to be dimerized and cleaved into an 
active caspase. They are involved in different biological processes and are grouped based on 
their function. For cell apoptosis, caspase -3, -6, and -7 are the executioner caspases, while 
caspase -2, -8 -9, and -10 represent the initiators. However, caspase -1, -4, -5, and -12 are 
involved in inflammation (McIlwain et al. 2013).  
For many years, caspase-3 was associated only with cell death. However, an elegant study 
conducted by Burguillos and colleagues reveals a new role for executioner caspases in the 
microglia activation process. In this study, they discovered that active caspase-3 was 
implicated in microglia activation through the Toll-like receptor 4 (TLR4) upon stimulation 
by lipopolysaccharide (LPS), but without microglia cell death. Indeed, caspase-8 activates 
caspase-3, which in turn will cleave protein kinase c-d (PKC-d) leading to activation of IkB 
Kinase (IKK) complex that will cause release of NF-kB. Thereafter, NF-kB translocates to 
the nucleus and promotes gene expression of pro-inflammatory genes such as IL1b, NOS2, 
and TNFa. Thus, caspase-3 activation in microglia is linked to neurotoxicity. But why does 
caspase-3 not kill microglia cells? Activation of microglial caspase-3 through TLR signaling 
leads to upregulation of the cellular inhibitor of apoptosis proteins (cIAPs), which in turn will 
prevent further cleavage of caspase-3 subunit P19 to fully active P17 (Kavanagh et al. 2014). 
The catalytic site of caspase-3 is cyctein (Cys) 163. It can be inactivated by the S-
nitrosylation posttranslational modification conducted by NO that is added to cysteine thiol, 
resulting in protein S-nitrosylation. Conversely, S-nitrosylation is reversible; thus, caspase-3 
is denitrosylated by thioredoxin (Trx) (Benhar et al. 2008). Trx are highly conserved proteins 
(Lillig and Holmgren 2007) and exist in three forms: cytosolic (Trx1), mitochondrial (Trx2), 
and testis-specific (Trx3) (Jimenez et al. 2004). Trx proteins are able to transfer electrons 
from NAPDH to proteins via the NADPH-dependent enzyme thioredoxin reductase. 
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2. AIMS OF THE THESIS 
Microglia are the innate immune cells of the CNS. They have an impressive level of plasticity 
that makes them able to adapt to changes in their microenvironment. Gliomas recruit 
microglia, which in turn promote their expansion and invasion. The general aim of my studies 
was to define the role for molecular mechanisms within microglia and glioma 
communication, and to decipher the epigenetic control in cellular reprogramming of 
microglia during the course of the disease. 
 
Specific aims of the projects: 
 
Paper I 
To study the role of histone modifications, especially H4K16ac in microglia polarization 
toward tumor promoting phenotype. 
 
Paper II 
To investigate a potential involvement of H3K27me3 modifiers enzymes, EZH2 and 
JMJD3/UTX in the regulation of tumor associated microglia in the context of pHGG and 
DIPG. 
 
Paper III 
To explore how caspase 3 signaling pathway is implicated in the activation of glioma 
associated microglia.  
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3. RESULT AND DISCUSSION 
Paper I.  Glioma-induced SIRT1-dependent activation of hMOF histone H4 lysine 16 
acetyltransferase in microglia promotes a tumor-supporting phenotype 
In this study, we first measured and quantified the microglial global amount of H4K16ac in 
both in vitro and in vivo models upon glioma-induced microglia activation. To explore in 
vitro the effect of glioma stimuli on microglia, we performed a cell segregated co-culture 
approach that was used for all the co-culture experiments in this study. In this setting, 
microglia were seeded in the upper compartment, while we cultured glioma cell lines from 
different origins at the bottom of the dish. Thereby, microglia cells were stimulated through  
soluble factors in the medium originating from glioma cells.  
To investigate microglia activation in response to glioma-released factors, gene expression 
profiling and functional assays were carried out in microglia. Of note, a recent study 
demonstrates that rat C6 glioma has a similar immune microenvironment to human 
glioblastomas (Gieryng et al. 2017a). We observed that C6 gliomas migrate further in the 
presence of BV2 microglia. Furthermore, we detected induction of a tumor-supporting 
phenotype in BV2 microglia. Using quantitative PCR (QPCR), we found that the mRNA 
expression of the inflammatory marker NOS2 was downregulated, whilst there was an 
upregulation of the tumor-supportive markers IL6, IL1b, CCL22, YM1, and MMP14 in BV2 
cells upon segregated co-culture with the C6 glioma cell line for 4h (Fig. 1a). Notably, IL6 
signaling maintains microglia tumor-supporting functions and promotes glioma malignancy 
by supporting glioma stem cell growth (Wang et al. 2009; Zhang et al. 2012)  
Interestingly, in BV2 cells subject to co-culture with the C6 glioma cell line at 2h, we 
detected a transient decrease of H4K16ac global protein level, followed by a significant 
increase at 4h, 6h, and 24h without affecting microglial H4 levels (Fig. 1e-f; Supplementary 
Fig. 1a-b).  
Likewise, we found a similar upregulation of H4K16ac in BV2 microglia segregated co-
cultured with glioma cells of distinct origins, including the GL261 glioma cells and murine 
primary glioma tumor spheres (Supplementary Fig. 1c-f). Notably, H4K16ac is a hallmark of 
accessible chromatin and an important modulator of transcriptional activation. The balance of 
the H4K16 acetylation level is regulated by the histone acetyltransferase hMOF and the 
deacetylase SIRT1. For instance, SIRT1 is implicated in various biological processes. SIRT1 
reduction leads to aging and memory deficit mediated by Tau through the upregulation of 
IL1b (Cho et al. 2015).  
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The microglial hMOF protein level was not found to be altered upon glioma co-culture 
conditions, suggesting that the observed increase of H4k16 acetylation level was not due to 
an aberrant protein expression level of the acetyltransferase hMOF (Fig. 3c). Conversely, the 
observed upregulation of H4K16ac correlates with an accumulation of SIRT1 in the BV2 
microglia nucleus upon exposure to glioma cells at 4h (Fig. 3e-g). However, the transient 
downregulation of the SIRT1 protein level was due to proteasomal degradation in response to 
glioma stimuli (Supplementary Fig. 3c). Indeed, the nucleo-cytoplasmic shuttling of SIRT1 is 
mediated by two nuclear localization signals and two nuclear export signals.  SIRT1 exhibits 
various functions depending on subcellular compartments, where it can be affected by 
specific posttranslational modifications.   
To validate the in vitro results, we used an established in vivo GL261 glioma model. This 
model has been used extensively to study the immune microenvironment of gliomas. This 
glioma model benefits our study because it has limited infiltration by peripheral 
monocytes/macrophages (Müller et al. 2015). Using confocal microscopy, the fluorescence 
intensity quantification of microglia in the brain tissue surrounding the gliomas at 1 and 2 
weeks after transplantation revealed a high abundance of H4K16ac in microglia cells located 
inside the tumor mass, as compared to cells residing at a distance from the tumor (Fig. 2a-c 
and Supplementary Fig. 2). Likewise, we found that SIRT1 was highly expressed in 
microglia nuclei inside the tumor as compared to the non-tumor area (Fig. 4 and 
Supplementary Fig. 4).  
This implies that the microglia protumoral phenotype in glioma involves SITR1 nuclear 
translocation, accompanied by a high level of H4K16ac in BV2 cells. This finding appears to 
counteract the intrinsic deacetylase activity of SIRT1 on H4K16ac.  
At first, these observations may sound contradictory; however, it is important to note that 
SIRT1 can be both a negative direct and positive indirect modulator of the H4K16 acetylation 
level. Indeed, the deacetylase SIRT1 directly decrease the expression level of this histone 
posttranslational modification . However, autoacetylation of hMOF reduces its enzymatic 
activity against H4K16ac. The autoacetylated hMOF at its lysine residue Lys274, can be 
activated via deacetylation by SIRT1 and, in turn, induce H4K16 acetylation (Michan and 
Sinclair 2007; Zhang et al. 2011) 
Based on these observations, we investigated SIRT1 and hMOF protein interactions by co-
immunoprecipitation (coIP) and in situ proximity ligation assay (PLA) First, we found that 
SIRT1 and hMOF protein-protein interaction increased in microglia under segregated co-
culture conditions with glioma cells for 4h (Fig. 5a-c). The increase of SIRT1 and hMOF 
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interaction in glioma-induced microglia correlates to a decrease in microglial basal acetylated 
hMOF upon co-culture for 4h, which was illustrated using anti-acetylated lysine  
immunoprecipitated protein complexes and PLA (Fig. 5d-f). Finally, we observed significant 
hMOF recruitment by chromatin immunoprecipitation (ChIP), coupled with higher H4K16ac 
enrichment at the Il6, IL1b, Mmp14, Ccl22, and Chil3 promoter regions (Fig. 6a-j). However, 
SIRT1 was not recruited at these promoter regions in microglia cells upon glioma stimulation 
(Supplementary Fig. 5). These data strengthen our hypothesis that activation of microglia by 
glioma cells induces translocation of SIRT1 into the nucleus of microglia cells, which will 
deacetylate hMOF, leading to its recruitment and acetylation of H4K16 at the promoter of 
microglial tumor-supportive markers. 
Our next step was to investigate the functional outcome of H4K16 acetylation level per se on 
microglia activation toward the pro-tumoral phenotype. To manipulate acetylation of H4K16, 
we took advantage of the intrinsic enzymatic effect of histone deacetylase SIRT1 or 
acetyltransferase hMOF on H4K16ac. BV2 cells were pretreated either with small interfering 
RNA (siRNA) against SIRT1 or EX527, a selective SIRT1 inhibitor that results in 
upregulation of H4K16 acetylation. Activating SIRT1 with SRT1720 reduces the acetylation 
of this histone mark. Therefore, the increase of H4K16ac in microglia promotes the migration 
ability of gliomas as compared to untreated (the control ones) BV2 microglia (Fig. 7c, e, and 
f). In contrast, downregulation of H4K16ac in microglia through activation of SIRT1 
decreases glioma migration. In agreement, similar effects on glioma migration ability were 
observed when the H4K16 acetylation expression level decreased due to hMOF gene 
expression silencing in microglia (Fig. 7g-h). 
Taken together, our data indicate that, in the context of glioma-induced microglia activation, 
microglial SIRT1 primarily mediates its effect via the deacetylation of hMOF that, in turn, 
will enhance the recruitment of this H4K16 histone acetyltransferase to the chromatin and, 
subsequently, transcriptional activation of specific microglia target genes. Next, we 
demonstrated that H4K16 acetylation balance mediated directly by the intrinsic activity of 
SIRT1 and hMOF affects microglia polarization toward the tumor-supporting phenotype in 
glioma biology (Fig. 8) (Figure 5).   
Paper II.  Inhibition of EZH2 or JMJD3 reduces microglial pro-tumoral activation in 
Diffuse Intrinsic Pontine Glioma 
Similar to other gliomas, microglia constitute approximately one-third of the cellular mass of 
DIPG (Caretti et al. 2014). In DIPG and pediatric high-grade gliomas, the functional role of 
infiltrating pontine microglia as well as their molecular profile remain elusive. In this project, 
we aim to explore how DIPGs affect microglia activation.  
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Thus, we used an in vitro segregated co-culture setting, where we seed BV2 microglia cells in 
the upper compartment; a monolayer of primary human DIPG cell line SF8628 or pHGGs 
(pediatric high-grade glioma) of human cell line SF188 are cultured at the bottom of the dish. 
The microglia and glioma will exchange secreted factors in the medium. 
To elucidate the activation profile of BV2 microglia in the context of DIPG and pHGGs, we 
used a functional assay and found that microglia promote both SF188 and SF8628 invasion 
ability (Fig. 1B-C). In addition, we analyzed NOS2 and IL6 gene expression upon 4h co-
culture. In line with other gliomas, we observed a significant downregulation of NOS2 and an 
upregulation of IL6 in DIPG-induced microglia. Strikingly, pHGGS-induced microglia have 
a non-inflammatory profile marked by a strong decrease in NOS2 and unchangeable basal 
microglial IL6 expression level (Fig. 1D-E). This indicates that microglia display various 
activation states in response to gliomas of different origins. 
Since DIPGs harbor a global loss in H3K27me3, we further investigated the impact of this 
histone mark on microglia activation in the context of DIPG and pHGG that have a steady 
H3K27me3 state. We quantified H3K27me3’s total protein level by immunoblot in BV2 
microglia under co-culture, with either DIPG or pHGG for 4h. We detected a significant 
reduction of H3K27me3, while H3 expression was not altered in both conditions (Fig. 2).   
H3K27me3 levels are regulated by the histone demythelase KDM6 enzymes named JMJD3 
and UTX that counteract the histone methyltransferase EZH2. We further investigated the 
histone modifying enzyme(s) involved in the regulation of H3K27 trimethylation observed in 
microglia upon their activation by glioma cells SF8628 and SF188 at 4h and observed a 
downregulation of microglial JMJD3 mRNA expression, while there is no significant 
alteration in the mRNA expression level of UTX and EZH2, except for a slight decrease of 
UTX gene expression in microglia co-cultured with SF8628 (Fig. 2E). Our data suggests that 
tumor-associated BV2 microglia in DIPG or pHGG is coupled with a downregulation of 
H3K27me3 and the demethylase JMJD3, which appear to be contradictory. Strikingly, ChIP 
assessments show that JMJD3 was recruited to genes enriched with the activation mark 
H3K4me3 rather than with H3K27me3 upon LPS treatment in macrophages in vitro and in 
vivo (Figure 5) (De Santa et al. 2009). 
In fact, the discovery of KDM6 demethylases changed our views from the original 
perspective that H3K27 methylation was not catalytically reversible. Thus, JMJD3 and UTX 
modulate H3K27me3 dynamics. However, they have a limited impact on genome-wide 
H3K27me3 steady-state homeostasis. For instance, a dramatic loss of H3K27me3 has been 
shown in the promoter of HOX genes in mouse embryonic fibroblasts (MEFs) UTX /JMJD3-
deficient. This observation suggests an additional mechanism for H3K27 demethylation that 
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remains unclear (Bosselut 2016). JMJD3 is an important regulator of microglia polarization. 
EZH2 gene expression was also found to rapidly upregulate in microglia, subject to LPS-
mediated TLR4 stimulation (Das et al. 2017b). Interestingly, it has been reported that 
inhibition of JMJD3 or EZH2 small molecule inhibitors reduces tumor growth in DIPG in 
vivo and in vitro. Thus, our next step was to investigate the effect of those inhibitors on the 
functional outcome of microglia in the context of DIPG and pHGG biology. It is clear that 
pretreating BV2 microglia with JMJD3 inhibitor GSKJ1 has a negative effect on SF188 and 
SF8628 invasion (Fig 3C-D). Concordantly, increased intrinsic JMJD3 suppresses LPS-
induced microglial pro-inflammatory activation and promotes alternative activation of M2 
microglia (Tang et al. 2014; Das et al. 2017a).  
Similarly, pretreating microglia with EZH2 inhibitor GSK343 leads to a potent decrease of 
the invasion ability of SF188 and SF8628 (Fig 3C-D). In contrast, the use of the same EZH2 
inhibitor in SF8628 DIPG or the SF188 pHGG prior to co-culture with BV2 microglia was 
not able to suppress microglia tumor-supporting phenotype activation illustrated by NOS2 
gene expression (Fig. 4B). This data indicates that microglia could influence the biology and 
treatment of DIPG or pHGG. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Histone modification associated with microglia polarization. 
Adapted and modified from (Cheray and Joseph 2018) 
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Paper III.   Glioma-induced inhibition of caspase-3 in microglia promotes a tumor-
supportive phenotype 
Previously, our lab reported a new role for executioner caspases in the microglia activation 
process. Microglia treated with LPS have high caspase-3-like activity, which induces 
microglial inflammatory response (Burguillos et al. 2011). Therefore, since caspase-3 is 
involved in the activation of microglia pro-inflammatory phenotype, we aimed to investigate 
whether the same signaling is occurring in microglia activation in the context of brain cancer.  
We grew different microglia cells with glioma cells from distinct origins in a co-culture 
setting and quantified microglia caspase activity in response to glioma stimuli. We detected a 
decrease in microglial caspase-3 activity (Fig. 1a-g). Thus, glioma shut down caspase-3 
activity in microglia. We observed a higher decrease of cleaved caspase-3 in Iba1 positive 
microglia inside the tumor as compared to microglia in the border reaching the tumor when 
we used an in vivo GL261 glioma model (Fig. 1h-j). Therefore, even in vivo, a glioma is able 
to repress caspase-3 activity in microglia cells. Next, we investigated the functional outcome 
of the low caspase-3 activity in microglia. Removal of capase-3 from microglia cells using 
siRNA leads to overexpression of the marker linked to the microglia tumor-supporting 
phenotype (IL6, CCL22, Ym1, and MMP14) while NOS2, a pro-inflammatory marker, 
decreased dramatically in microglia (Fig. 2a-d). 
 Moreover, we found that the caspase-3 knockdown in microglia helps gliomas to migrate 
and invade more as compared to microglia transfected with siRNA control (Fig. 2e).  These 
data indicate that decrease of caspase-3 activity in microglia polarize them toward tumor-
supportive phenotype.  
Therefore, we defined the mechanism that gliomas use to induce the decrease of caspase-3-
like activity in microglia. First, we examined the effect of the NOS2-derived NO exchanged 
between microglia and glioma on caspase-3 activity in microglia. We reported that an NOS2-
specific inhibitor (1400W) prevents glioma induced-caspase-3 activity reduction in microglia 
(Fig 4a). Furthermore, using biotin-switch method and PLA techniques, we found that the 
active site of caspase-3 was S-nitrosylated at the cysteine residue in microglia cells after 
exposure to glioma cells (Fig 4b-c). For instance, the complete inhibition of NOS2 mRNA 
expression by siRNA in glioma or microglia led us to figure out that the NO produced and 
secreted by glioma and not microglia, causes S-nitrosylation of caspase-3 and thereby it 
becomes inactivated (Fig 4d-f). Finally, we revealed that the reduction of basal microglial 
caspase-3 activity and accumulation of SNO-procaspase-3 in the mitochondria in microglia is 
due to glioma-induced inhibition of thioredoxin-2 activity (Fig. 5c-d). Indeed, the knockdown 
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of Trx2 in microglia mimics the glioma effects on microglia regarding the level of SNO-
procaspase-3 (Fig 5b). 
Ultimately, we validated our previous findings in vivo by blocking the upstream signaling. 
Thus, removing NO from the GFP-GL261 glioma cells before injecting them into the mouse 
brain via NOS2 shRNA causes a decrease in tumor formation and a potent reduction of 
microglia recruitment to the tumor site (Fig. 6c-f). To gain further insight of the downstream 
signaling pathway involved in glioma cell-microglia communication, we generated a 
microglial caspase-3 knockout model. When we implanted GFP-GL261 in 
Casp3flox/floxCX3cr1CreERT2, we observed the development of a bigger tumor than the control 
counterparts after 1 and 2 weeks after tumor transplantation (Fig 6b-e). 
In summary, we uncovered a novel key role for caspase-3 in the regulation of microglia 
activation. Gliomas recruit microglia and reprogram them by producing NOS2-derived NO, 
leading to accumulation of S-nitrosylated caspase-3 in microglial mitochondria due to 
glioma-induced inhibition of thioredoxin-2 activity. Therefore, gliomas inhibit microglial 
basal caspase-3 activity for their expansion and invasion (Shen et al. 2018) (Figure 6).  
 
 
Figure 6. Caspase-3 regulate microglia tumor supporting phenotype in glioma. 
Adapted from (Grauwet and Chiocca 2016) 
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4. CONCLUSION AND PERSECTIVES 
Paper I: 
During glioma-microglia cell communication, microglia undergo epigenetic reprogramming. 
We discovered that a glioma induces an increase of H4K16ac in microglia due to 
accumulation of SIRT1 in microglial nucleus, which in turn deacetylates hMOF, leading to 
its chromatin recruitment and upregulation of its enzymatic activity against H4K16ac at the 
promoter of specific microglia tumor-supporting genes. It is worth investigating the 
mechanisms that the glioma uses to induce nuclear translocation of microglial SIRT1; it could 
be due to oxidative stress generated by the glioma (Nasrin et al. 2009). In addition, the 
balance of the H4K16 acetylation level is critical for microglia plasticity in glioma biology.  
 Paper II: 
In this study, we bring knowledge on how microglia cells are regulated in the H3K27M 
mutant DIPG context, wherein microglia activation toward the tumor-supporting phenotype 
is associated with a potent decrease of H3K27me3 and aberrant JMJD3 gene expression. 
Moreover, inhibiting histone enzymes EZH2 or JMJD3/UTX in microglia cells is reduced, 
which in turn decreases DIPG invasion. However, the investigations can be extended to 
decipher the signaling pathway that causes the global decrease of H3K27me3 in tumor-
associated microglia and identify the downstream targets of JMJD3 and their involvement in 
microglia polarization. It is important to validate the effect of EZH2 and JMJD3/UTX 
inhibitors on DIPG microenvironment in vivo. 
Paper III: 
Caspase-3 may work as a rheostat, which controls the microglia cell fate in response to 
diverse stimuli, where low activity and reduced basal caspase-3 activity regulate, 
respectively, the pro-inflammatory and the tumor-supporting microglial activation states. It is 
of interest to identify mechanistically how low caspase-3 activity induces the polarization of 
microglia toward the tumor-supporting phenotype. 
 
 
 
 
 
 30 
 
 
5. ACKNOWLEDGEMENTS 
I want to acknowledge all the people that I have met or have been working with me during 
my PhD study at Karolinska Institutet. 
First and foremost, I would like to express my sincere gratitude to my principal supervisor 
Bertrand Joseph. It is impossible to put into words how grateful I am for your guidance and 
moral support. You have opened the door to the world of academic research for me. Without 
your persistent patience of explaining questions to me and discussing all the details with me, I 
could not have done the thesis. You have always been encouraging and have made me 
believe that I might be doing a better job than I thought. The freedom you granted me for my 
work led to the number of results presented here.  
I want to thank my co-supervisors Nina Heldring and Ola Hermanson, for good 
collaboration and for your time and your insightful advices. I appreciate your support. 
It has been a great joy working with my collaborators Klas Blomgren and Ahmed Osman 
Thank you for your collaboration and exciting ideas. I feel fortunate to have had the chance to 
work with you. Thank you, Ahmed, for being always available to help and for your 
professional way in work. 
I would like to thank all the former and current members of the pink group, without your 
help, this thesis would not have existed. Popi Thanks for caring and for always keeping the 
mood up. I appreciate your advice to me and your support. Your positive personality inspires 
me. Mathilde, you are an appreciated colleague, and I enjoyed working and sharing the 
office with you. Thanks for helping in answering my theoretical and practical questions. 
Vassilis, you have a great sense of humor. Thanks for the “party times” in the lab. Your help 
was invaluable in getting nice confocal microscopy images. Special thanks to Olle, your flow 
of ideas, motivation, and hard work are inspiring. You taught me many techniques, and you 
always had time to help me when I have a problem with experiments. Kathleen, thanks for 
being so kind and sharing your expertise in microglia. It was fun discussing science with you. 
Thanks, Lara for being a friendly colleague. I appreciate your help, and I wish you the best 
with your PhD project. Julia, your passion for science inspires me. Thanks for the great time 
we had at CCK and outside the work sometimes. I would also want to thank Rachel for 
working together with me and for being so dedicated.   
My PhD life would not have been so much fun without Patricia and Xianli. You have been 
excellent friends and colleagues. Thanks for the great time we had at work and outside. It was 
tough, and you were always there. Thanks for given of your time, energy, and expertise to 
help me in research and life.  
  31 
 
 
Also, former group members Jens and Johanna who gave valuable feedback, for which I 
would like to thank them.  Maria, thanks for your warm-heart and your great help. Thanks 
also to Hanzhao, Mimmi, Jeremy, Alex, and Agata, I wish you the best in your future life. 
I would like to thank all the members of Boris Zhivotovsky’s group. I have enjoyed our 
group meeting and “fika.” 
It is impossible to mention all my colleagues at CCK you all made the department such an 
enjoyable place. Thanks to Pedro, Rainer, Muyi, Ishani, Yuanyuan, Vicky, Ran, Ali, 
Dimitris and Aravindh for being always friendly and helpful.Thanks to all the people I have 
met during my PhD studies at IMM. Mizan, it was always fun talking with you about science 
and general things in life. Thanks to Imran, Jeremy and Aymen, you have been supportive 
in many ways. I also want to thank my friends at Karolinska Institutet Jelena and Evi. 
Erika Rindsjö, Sören, Jenny Svedman, Lisa and Åsa Lycke and all members of 
Karolinska Institutet’s staff were very helpful with administrative issues. I am very grateful to 
you for making it so easy. 
My gratitude also goes to my family and friends in Sweden. Special thanks to Lars for his 
warm and supportive friendship. We Have enjoyed dinners with you. Thanks for being 
always helpful. I would like to thank Karin & Noamen, Sara & Sara, Lina & Aymen and 
Victoria & Hamadi for the wonderful weekends and happy time we shared. Special thanks 
to Khaled who has continuously encouraged me whenever I felt frustrated.  
My friends who are spread around the world: Abyr, Douaa, and Souha thanks for still caring 
despite my lack of courtesy when it comes to staying in touch. Your friendship is so valuable 
to me. 
My family thanks for bringing even more joy to my short visits back home. You have always 
been in my heart! 
Many thanks to my husband Amine for his endless love, patience, and support. Without you, 
my journey would have never been the same. I was continually amazed by your willingness 
to help me and to proofread pages of meaningless biology. You have experienced all of the 
ups and downs of my PhD and life. I love you! I want to thank Amine’s family who has 
made my every single visit to Tunisia so exciting. 
Last but not least, I want to thank my parents for their unconditional love and support, 
without whom I would never have enjoyed so many opportunities. I hope this will make them 
proud and make up for the missing time. This thesis is dedicated to my father’s soul for his 
tough fight with cancer. 

  33 
 
 
6. REFERENCES 
 
2018. Stephen Paget and the ‘seed and soil’ theory of metastatic dissemination | 
SpringerLink. 
Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Canaani E, 
Salcini AE, Helin K. 2007. UTX and JMJD3 are histone H3K27 demethylases 
involved in HOX gene regulation and development. Nature 449: 731-734. 
Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM. 2011. Infiltrating monocytes 
trigger EAE progression, but do not contribute to the resident microglia pool. Nat 
Neurosci 14: 1142-1149. 
Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. 2007. Local self-renewal can sustain 
CNS microglia maintenance and function throughout adult life. Nat Neurosci 10: 
1538-1543. 
Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, Pillus L, Reinberg D, Shi Y, 
Shiekhattar R et al. 2007. New nomenclature for chromatin-modifying enzymes. in 
Cell, pp. 633-636, United States. 
Aloia L, Di Stefano B, Di Croce L. 2013. Polycomb complexes in stem cells and embryonic 
development. Development 140: 2525-2534. 
Anekonda TS, Reddy PH. 2006. Neuronal protection by sirtuins in Alzheimer's disease. J 
Neurochem 96: 305-313. 
Araki T, Sasaki Y, Milbrandt J. 2004. Increased nuclear NAD biosynthesis and SIRT1 
activation prevent axonal degeneration. Science 305: 1010-1013. 
Arcipowski KM, Martinez CA, Ntziachristos P. 2016. Histone demethylases in physiology 
and cancer: A tale of two enzymes, JMJD3 and UTX. Curr Opin Genet Dev 36: 59-
67. 
Askew K, Li K, Olmos-Alonso A, Garcia-Moreno F, Liang Y, Richardson P, Tipton T, 
Chapman MA, Riecken K, Beccari S et al. 2017. Coupled Proliferation and Apoptosis 
Maintain the Rapid Turnover of Microglia in the Adult Brain. Cell Rep 18: 391-405. 
Badie B, Schartner JM. 2000. Flow cytometric characterization of tumor-associated 
macrophages in experimental gliomas. Neurosurgery 46: 957-961; discussion 961-
952. 
Ballabh P, Braun A, Nedergaard M. 2004. The blood-brain barrier: an overview: structure, 
regulation, and clinical implications. Neurobiol Dis 16: 1-13. 
Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. 
2007. High-resolution profiling of histone methylations in the human genome. Cell 
129: 823-837. 
 34 
 
 
Benda P, Lightbody J, Sato G, Levine L, Sweet W. 1968. Differentiated rat glial cell strain in 
tissue culture. Science 161: 370-371. 
Benhar M, Forrester MT, Hess DT, Stamler JS. 2008. Regulated protein denitrosylation by 
cytosolic and mitochondrial thioredoxins. Science 320: 1050-1054. 
Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, Mulinyawe 
SB, Bohlen CJ, Adil A, Tucker A et al. 2016. New tools for studying microglia in the 
mouse and human CNS. 
Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. 2009. An operational definition of 
epigenetics. Genes Dev 23: 781-783. 
Bettinger I, Thanos S, Paulus W. 2002. Microglia promote glioma migration. Acta 
Neuropathol 103: 351-355. 
Bird A. 2007. Perceptions of epigenetics. Nature 447: 396-398. 
Blanchard F, Kinzie E, Wang Y, Duplomb L, Godard A, Held WA, Asch BB, Baumann H. 
2002. FR901228, an inhibitor of histone deacetylases, increases the cellular 
responsiveness to IL-6 type cytokines by enhancing the expression of receptor 
proteins. Oncogene 21: 6264-6277. 
Boche D, Perry VH, Nicoll JA. 2013. Review: activation patterns of microglia and their 
identification in the human brain. Neuropathol Appl Neurobiol 39: 3-18. 
Bosselut R. 2016. Pleiotropic functions of H3K27Me3 demethylases in immune cell 
differentiation. Trends Immunol 37: 102-113. 
Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, Wernig M, 
Tajonar A, Ray MK et al. 2006. Polycomb complexes repress developmental 
regulators in murine embryonic stem cells. Nature 441: 349-353. 
Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. 2006. Genome-wide mapping of 
Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 20: 
1123-1136. 
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, 
Chakravarty D, Sanborn JZ, Berman SH et al. 2013. The somatic genomic landscape 
of glioblastoma. Cell 155: 462-477. 
Buckner JC. 2003. Factors influencing survival in high-grade gliomas. Semin Oncol 30: 10-
14. 
Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A, Cano J, 
Brundin P, Englund E, Venero JL et al. 2011. Caspase signalling controls microglia 
activation and neurotoxicity. Nature 472: 319-324. 
Caretti V, Sewing AC, Lagerweij T, Schellen P, Bugiani M, Jansen MH, van Vuurden DG, 
Navis AC, Horsman I, Vandertop WP et al. 2014. Human pontine glioma cells can 
induce murine tumors. Acta Neuropathol 127: 897-909. 
  35 
 
 
Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James 
CD, Jenkins R et al. 2013. The histone H3.3K27M mutation in pediatric glioma 
reprograms H3K27 methylation and gene expression. Genes Dev 27: 985-990. 
Chen R, Smith-Cohn M, Cohen AL, Colman H. 2017a. Glioma Subclassifications and Their 
Clinical Significance. Neurotherapeutics 14: 284-297. 
Chen Z, Feng X, Herting CJ, Garcia VA, Nie K, Pong WW, Rasmussen R, Dwivedi B, Seby 
S, Wolf SA et al. 2017b. Cellular and Molecular Identity of Tumor-Associated 
Macrophages in Glioblastoma. Cancer Res 77: 2266-2278. 
Cheray M, Joseph B. 2018. Epigenetics Control Microglia Plasticity. Front Cell Neurosci 12. 
Cho SH, Chen JA, Sayed F, Ward ME, Gao FY, Nguyen TA, Krabbe G, Sohn PD, Lo I, 
Minami S et al. 2015. SIRT1 Deficiency in Microglia Contributes to Cognitive 
Decline in Aging and Neurodegeneration via Epigenetic Regulation of IL-1 beta. 
Journal of Neuroscience 35: 807-818. 
Choudhari SK, Chaudhary M, Bagde S, Gadbail AR, Joshi V. 2013. Nitric oxide and cancer: 
a review. World J Surg Oncol 11: 118. 
Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. 1995. Expression of nitric oxide 
synthase in human central nervous system tumors. Cancer Res 55: 727-730. 
Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, Segall JE. 2012. 
Microglial stimulation of glioblastoma invasion involves epidermal growth factor 
receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol 
Med 18: 519-527. 
Cosgrove MS, Boeke JD, Wolberger C. 2004. Regulated nucleosome mobility and the 
histone code. Nat Struct Mol Biol 11: 1037-1043. 
Cunningham CL, Martinez-Cerdeno V, Noctor SC. 2013. Microglia regulate the number of 
neural precursor cells in the developing cerebral cortex. J Neurosci 33: 4216-4233. 
Das A, Arifuzzaman S, Yoon T, Kim SH, Chai JC, Lee YS, Jung KH, Chai YG. 2017a. RNA 
sequencing reveals resistance of TLR4 ligand-activated microglial cells to 
inflammation mediated by the selective jumonji H3K27 demethylase inhibitor. Sci 
Rep 7: 6554. 
-. 2017b. RNA sequencing reveals resistance of TLR4 ligand-activated microglial cells to 
inflammation mediated by the selective jumonji H3K27 demethylase inhibitor. 
Scientific Reports 7: 6554. 
Davies DC. 2002. Blood-brain barrier breakdown in septic encephalopathy and brain 
tumours. J Anat 200: 639-646. 
De Santa F, Narang V, Yap ZH, Tusi BK, Burgold T, Austenaa L, Bucci G, Caganova M, 
Notarbartolo S, Casola S et al. 2009. Jmjd3 contributes to the control of gene 
expression in LPS-activated macrophages. Embo j 28: 3341-3352. 
DeWitt JC, Mock A, Louis DN. 2017. The 2016 WHO classification of central nervous 
system tumors: what neurologists need to know. Curr Opin Neurol 30: 643-649. 
 36 
 
 
Donmez G. 2012. The neurobiology of sirtuins and their role in neurodegeneration. Trends 
Pharmacol Sci 33: 494-501. 
Durham BS, Grigg R, Wood IC. 2017. Inhibition of histone deacetylase 1 or 2 reduces 
induced cytokine expression in microglia through a protein synthesis independent 
mechanism. J Neurochem 143: 214-224. 
Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin 
SB, Herman JG. 2000. Inactivation of the DNA-repair gene MGMT and the clinical 
response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354. 
Ezponda T, Dupéré-Richer D, Will CM, Small EC, Varghese N, Patel T, Nabet B, Popovic R, 
Oyer J, Bulic M et al. 2017. UTX/KDM6A Loss Enhances the Malignant Phenotype 
of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition. Cell Rep 21: 628-640. 
Fomchenko EI, Holland EC. 2006. Mouse models of brain tumors and their applications in 
preclinical trials. Clin Cancer Res 12: 5288-5297. 
Francis NJ, Kingston RE, Woodcock CL. 2004. Chromatin compaction by a polycomb group 
protein complex. Science 306: 1574-1577. 
Fullgrabe J, Kavanagh E, Joseph B. 2011. Histone onco-modifications. Oncogene 30: 3391-
3403. 
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by 
tumours. Nat Rev Immunol 12: 253-268. 
Gan L, Mucke L. 2008. Paths of convergence: sirtuins in aging and neurodegeneration. 
Neuron 58: 10-14. 
Gielen PR, Schulte BM, Kers-Rebel ED, Verrijp K, Petersen-Baltussen HM, ter Laan M, 
Wesseling P, Adema GJ. 2015. Increase in both CD14-positive and CD15-positive 
myeloid-derived suppressor cell subpopulations in the blood of patients with glioma 
but predominance of CD15-positive myeloid-derived suppressor cells in glioma 
tissue. J Neuropathol Exp Neurol 74: 390-400. 
Gieryng A, Pszczolkowska D, Bocian K, Dabrowski M, Rajan WD, Kloss M, Mieczkowski 
J, Kaminska B. 2017a. Immune microenvironment of experimental rat C6 gliomas 
resembles human glioblastomas. Sci Rep 7: 17556. 
Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B. 2017b. Immune 
microenvironment of gliomas. Lab Invest 97: 498-518. 
Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng 
LG, Stanley ER et al. 2010. Fate mapping analysis reveals that adult microglia derive 
from primitive macrophages. Science 330: 841-845. 
Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. 2013. Origin and differentiation of 
microglia. Front Cell Neurosci 7: 45. 
Gorisch SM, Wachsmuth M, Toth KF, Lichter P, Rippe K. 2005. Histone acetylation 
increases chromatin accessibility. J Cell Sci 118: 5825-5834. 
  37 
 
 
Grauwet K, Chiocca EA. 2016. Glioma and microglia, a double entendre. Nature 
Immunology 17: 1240. 
Gwak HS, Park HJ. 2017. Developing chemotherapy for diffuse pontine intrinsic gliomas 
(DIPG). Crit Rev Oncol Hematol 120: 111-119. 
Hajji N, Wallenborg K, Vlachos P, Füllgrabe J, Hermanson O, Joseph B. 2010. Opposing 
effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the 
topoisomerase II inhibitor etoposide. Oncogene 29: 2192-2204. 
Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S. 2002. Identification 
of a factor that links apoptotic cells to phagocytes. Nature 417: 182-187. 
Hanisch UK. 2002. Microglia as a source and target of cytokines. Glia 40: 140-155. 
Hashizume R. 2017. Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. in 
Neurol Med Chir (Tokyo), pp. 331-342. 
Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, 
Ngo V et al. 2014. Pharmacologic inhibition of histone demethylation as a therapy for 
pediatric brainstem glioma. Nat Med 20: 1394-1396. 
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, 
Hainfellner JA, Mason W, Mariani L et al. 2005. MGMT gene silencing and benefit 
from temozolomide in glioblastoma. N Engl J Med 352: 997-1003. 
Hezroni H, Tzchori I, Davidi A, Mattout A, Biran A, Nissim-Rafinia M, Westphal H, 
Meshorer E. 2011. H3K9 histone acetylation predicts pluripotency and 
reprogramming capacity of ES cells. Nucleus 2: 300-309. 
Hisahara S, Chiba S, Matsumoto H, Tanno M, Yagi H, Shimohama S, Sato M, Horio Y. 
2008. Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear 
translocation. Proc Natl Acad Sci U S A 105: 15599-15604. 
Horikoshi N, Kumar P, Sharma GG, Chen M, Hunt CR, Westover K, Chowdhury S, Pandita 
TK. 2013. Genome-wide distribution of histone H4 Lysine 16 acetylation sites and 
their relationship to gene expression. Genome Integr 4: 3. 
Horten BC, Basler GA, Shapiro WR. 1981. Xenograft of human malignant glial tumors into 
brains of nude mice. A histopatholgical study. J Neuropathol Exp Neurol 40: 493-
511. 
Huszthy PC, Daphu I, Niclou SP, Stieber D, Nigro JM, Sakariassen PO, Miletic H, Thorsen 
F, Bjerkvig R. 2012. In vivo models of primary brain tumors: pitfalls and 
perspectives. Neuro Oncol 14: 979-993. 
Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. 2007. 
Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622. 
Jimenez A, Zu W, Rawe VY, Pelto-Huikko M, Flickinger CJ, Sutovsky P, Gustafsson JA, 
Oko R, Miranda-Vizuete A. 2004. Spermatocyte/spermatid-specific thioredoxin-3, a 
novel Golgi apparatus-associated thioredoxin, is a specific marker of aberrant 
spermatogenesis. J Biol Chem 279: 34971-34982. 
 38 
 
 
Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ, Becher OJ, Cho YJ, 
Gupta N, Hawkins C et al. 2017. Pediatric high-grade glioma: biologically and 
clinically in need of new thinking. in Neuro Oncol, pp. 153-161. 
Kavanagh E, Rodhe J, Burguillos MA, Venero JL, Joseph B. 2014. Regulation of caspase-3 
processing by cIAP2 controls the switch between pro-inflammatory activation and 
cell death in microglia. in Cell Death Dis, pp. e1565-. 
Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, Wieghofer P, 
Heinrich A, Riemke P, Holscher C et al. 2013. Microglia emerge from 
erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci 16: 
273-280. 
Kierdorf K, Prinz M. Microglia in steady state. in J Clin Invest, pp. 3201-3209. 
Koch CM, Andrews RM, Flicek P, Dillon SC, Karaoz U, Clelland GK, Wilcox S, Beare DM, 
Fowler JC, Couttet P et al. 2007. The landscape of histone modifications across 1% of 
the human genome in five human cell lines. Genome Res 17: 691-707. 
Kooistra SM, Helin K. 2012. Molecular mechanisms and potential functions of histone 
demethylases. Nat Rev Mol Cell Biol 13: 297-311. 
Langley RR, Fidler IJ. 2011. The seed and soil hypothesis revisited - the role of tumor-stroma 
interactions in metastasis to different organs. Int J Cancer 128: 2527-2535. 
Lapointe S, Perry A, Butowski NA. 2018. Primary brain tumours in adults. Lancet 392: 432-
446. 
Lee DL, Sasser JM, Hobbs JL, Boriskie A, Pollock DM, Carmines PK, Pollock JS. 2005. 
Posttranslational regulation of NO synthase activity in the renal medulla of diabetic 
rats. Am J Physiol Renal Physiol 288: F82-90. 
Li W, Graeber MB. 2012. The molecular profile of microglia under the influence of glioma. 
Neuro Oncol 14: 958-978. 
Li X, Corsa CA, Pan PW, Wu L, Ferguson D, Yu X, Min J, Dou Y. 2010. MOF and H4 K16 
acetylation play important roles in DNA damage repair by modulating recruitment of 
DNA damage repair protein Mdc1. Mol Cell Biol 30: 5335-5347. 
Lillig CH, Holmgren A. 2007. Thioredoxin and related molecules--from biology to health 
and disease. Antioxid Redox Signal 9: 25-47. 
Lin GL, Nagaraja S, Filbin MG, Suva ML, Vogel H, Monje M. 2018. Non-inflammatory 
tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol 
Commun 6: 51. 
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, 
Kleihues P. 2007. The 2007 WHO classification of tumours of the central nervous 
system. Acta Neuropathol 114: 97-109. 
Lu L, Li L, Lv X, Wu XS, Liu DP, Liang CC. 2011. Modulations of hMOF autoacetylation 
by SIRT1 regulate hMOF recruitment and activities on the chromatin. Cell Res 21: 
1182-1195. 
  39 
 
 
Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. 1997. Crystal structure of 
the nucleosome core particle at 2.8 A resolution. Nature 389: 251-260. 
Mack SC, Hubert CG, Miller TE, Taylor MD, Rich JN. 2015. An epigenetic gateway to brain 
tumor cell identity. Nature Neuroscience 19: 10-19. 
Mammana S, Fagone P, Cavalli E, Basile MS, Petralia MC, Nicoletti F, Bramanti P, Mazzon 
E. 2018. The Role of Macrophages in Neuroinflammatory and Neurodegenerative 
Pathways of Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Multiple 
Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. Int J 
Mol Sci 19. 
Markovic DS, Glass R, Synowitz M, Rooijen N, Kettenmann H. 2005. Microglia stimulate 
the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J 
Neuropathol Exp Neurol 64: 754-762. 
Markovic DS, Vinnakota K, Chirasani S, Synowitz M, Raguet H, Stock K, Sliwa M, 
Lehmann S, Kalin R, van Rooijen N et al. 2009. Gliomas induce and exploit 
microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A 
106: 12530-12535. 
Marvel D, Gabrilovich DI. 2015. Myeloid-derived suppressor cells in the tumor 
microenvironment: expect the unexpected. J Clin Invest 125: 3356-3364. 
McIlwain DR, Berger T, Mak TW. 2013. Caspase Functions in Cell Death and Disease. 
Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, 
Oliver JA, López R et al. 2012. MGMT promoter methylation status and MGMT and 
CD133 immunohistochemical expression as prognostic markers in glioblastoma 
patients treated with temozolomide plus radiotherapy. in J Transl Med, p. 250. 
Mellert HS, McMahon SB. 2009. hMOF, a KAT(8) with many lives. Mol Cell 36: 174-175. 
Michan S, Sinclair D. 2007. Sirtuins in mammals: insights into their biological function. 
Biochem J 404: 1-13. 
Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, 
Bruck W, Priller J, Prinz M. 2007. Microglia in the adult brain arise from Ly-
6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci 10: 1544-
1553. 
Misuraca KL, Hu G, Barton KL, Chung A, Becher OJ. 2016. A Novel Mouse Model of 
Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells12. in Neoplasia, 
pp. 60-70. 
Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, Zheng C, 
Johansen JV, Rapin N, Porse BT et al. 2017. EZH2 is a potential therapeutic target for 
H3K27M-mutant pediatric gliomas. Nature Medicine. 
Monje M, Mitra SS, Freret ME, Raveh TB, Kim J, Masek M, Attema JL, Li G, Haddix T, 
Edwards MS et al. 2011. Hedgehog-responsive candidate cell of origin for diffuse 
intrinsic pontine glioma. Proc Natl Acad Sci U S A 108: 4453-4458. 
 40 
 
 
Müller A, Brandenburg S, Turkowski K, Müller S, Vajkoczy P. 2015. Resident microglia, 
and not peripheral macrophages, are the main source of brain tumor mononuclear 
cells. Int J Cancer 137: 278-288. 
Nasrin N, Kaushik VK, Fortier E, Wall D, Pearson KJ, de Cabo R, Bordone L. 2009. JNK1 
phosphorylates SIRT1 and promotes its enzymatic activity. PLoS One 4: e8414. 
Nayak D, Roth TL, McGavern DB. 2014. Microglia development and function. Annu Rev 
Immunol 32: 367-402. 
Nimmerjahn A, Kirchhoff F, Helmchen F. 2005. Resting microglial cells are highly dynamic 
surveillants of brain parenchyma in vivo. Science 308: 1314-1318. 
Outeiro TF, Marques O, Kazantsev A. 2008. Therapeutic role of sirtuins in neurodegenerative 
disease. Biochim Biophys Acta 1782: 363-369. 
Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira 
TA, Guiducci E, Dumas L et al. 2011. Synaptic pruning by microglia is necessary for 
normal brain development. Science 333: 1456-1458. 
Perng P, Lim M. 2015. Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at 
Non-CNS Sites. Front Oncol 5: 153. 
Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman 
EJ, Ma Q, Takahashi YH, Woodfin AR et al. 2017. Therapeutic targeting of 
polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat 
Med 23: 493-500. 
Ransohoff RM. 2016. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci 
19: 987-991. 
Rea S, Xouri G, Akhtar A. 2007. Males absent on the first (MOF): from flies to humans. 
Oncogene 26: 5385-5394. 
Revollo JR, Li X. 2013. The ways and means that fine tune Sirt1 activity. Trends Biochem 
Sci 38: 160-167. 
Ridler C. 2017. Neuro-oncology: New therapeutic targets for diffuse intrinsic pontine glioma. 
Nature Reviews Neurology 13: 196. 
Rougeulle C, Chaumeil J, Sarma K, Allis CD, Reinberg D, Avner P, Heard E. 2004. 
Differential histone H3 Lys-9 and Lys-27 methylation profiles on the X chromosome. 
Mol Cell Biol 24: 5475-5484. 
Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou CL, Ransohoff RM, 
Charo IF. 2010. Selective chemokine receptor usage by central nervous system 
myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One 5: e13693. 
Salter MW, Stevens B. 2017. Microglia emerge as central players in brain disease. Nature 
Medicine 23: 1018. 
  41 
 
 
Sarkar S, Doring A, Zemp FJ, Silva C, Lun X, Wang X, Kelly J, Hader W, Hamilton M, 
Mercier P et al. 2013. Therapeutic activation of macrophages and microglia to 
suppress brain tumor-initiating cells. Ann Neurosci 20: 154. 
Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff 
RM, Greenberg ME, Barres BA, Stevens B. 2012. Microglia sculpt postnatal neural 
circuits in an activity and complement-dependent manner. Neuron 74: 691-705. 
Schneider R, Grosschedl R. 2007. Dynamics and interplay of nuclear architecture, genome 
organization, and gene expression. Genes Dev 21: 3027-3043. 
Schones DE, Cui K, Cuddapah S, Roh TY, Barski A, Wang Z, Wei G, Zhao K. 2008. 
Dynamic regulation of nucleosome positioning in the human genome. Cell 132: 887-
898. 
Shapiro WR, Basler GA, Chernik NL, Posner JB. 1979. Human brain tumor transplantation 
into nude mice. J Natl Cancer Inst 62: 447-453. 
Shen X, Venero JL, Joseph B, Burguillos MA. 2018. Caspases orchestrate microglia 
instrumental functions. Prog Neurobiol 171: 50-71. 
Shigemoto-Mogami Y, Hoshikawa K, Goldman JE, Sekino Y, Sato K. 2014. Microglia 
enhance neurogenesis and oligodendrogenesis in the early postnatal subventricular 
zone. J Neurosci 34: 2231-2243. 
Sielska M, Przanowski P, Wylot B, Gabrusiewicz K, Maleszewska M, Kijewska M, 
Zawadzka M, Kucharska J, Vinnakota K, Kettenmann H et al. 2013. Distinct roles of 
CSF family cytokines in macrophage infiltration and activation in glioma progression 
and injury response. J Pathol 230: 310-321. 
Sousa C, Golebiewska A, Poovathingal SK, Kaoma T, Pires-Afonso Y, Martina S, Coowar 
D, Azuaje F, Skupin A, Balling R et al. 2018. Single-cell transcriptomics reveals 
distinct inflammation-induced microglia signatures. in EMBO Rep. 
Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh 
AH, Bradner JE, Ligon KL, Brennan C et al. 2007. Coactivation of receptor tyrosine 
kinases affects the response of tumor cells to targeted therapies. Science 318: 287-
290. 
Stylli SS, Luwor RB, Ware TM, Tan F, Kaye AH. 2015. Mouse models of glioma. J Clin 
Neurosci 22: 619-626. 
Svotelis A, Bianco S, Madore J, Huppé G, Nordell-Markovits A, Mes-Masson AM, Gévry N. 
2011. H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene 
BCL2 determines ERα ligand dependency. in EMBO J, pp. 3947-3961. 
Szulzewsky F, Pelz A, Feng X, Synowitz M, Markovic D, Langmann T, Holtman IR, Wang 
X, Eggen BJ, Boddeke HW et al. 2015. Glioma-associated microglia/macrophages 
display an expression profile different from M1 and M2 polarization and highly 
express Gpnmb and Spp1. PLoS One 10: e0116644. 
 42 
 
 
Tam WY, Ma CHE. 2014. Bipolar/rod-shaped microglia are proliferating microglia with 
distinct M1/M2 phenotypes. in Sci Rep. 
Tang Y, Li T, Li J, Yang J, Liu H, Zhang XJ, Le W. 2014. Jmjd3 is essential for the 
epigenetic modulation of microglia phenotypes in the immune pathogenesis of 
Parkinson's disease. Cell Death Differ 21: 369-380. 
Tie F, Banerjee R, Stratton CA, Prasad-Sinha J, Stepanik V, Zlobin A, Diaz MO, Scacheri 
PC, Harte PJ. 2009. CBP-mediated acetylation of histone H3 lysine 27 antagonizes 
Drosophila Polycomb silencing. Development 136: 3131-3141. 
Tremblay ME, Lowery RL, Majewska AK. 2010. Microglial interactions with synapses are 
modulated by visual experience. PLoS Biol 8: e1000527. 
Ueno M, Fujita Y, Tanaka T, Nakamura Y, Kikuta J, Ishii M, Yamashita T. 2013. Layer V 
cortical neurons require microglial support for survival during postnatal development. 
Nat Neurosci 16: 543-551. 
Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, 
Bernard D, Vanderwinden JM et al. 2006. The Polycomb group protein EZH2 
directly controls DNA methylation. Nature 439: 871-874. 
Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. 2009. Resting microglia directly 
monitor the functional state of synapses in vivo and determine the fate of ischemic 
terminals. J Neurosci 29: 3974-3980. 
Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, 
Gallagher J, Schuschu J et al. 2009. Targeting interleukin 6 signaling suppresses 
glioma stem cell survival and tumor growth. Stem Cells 27: 2393-2404. 
Wei J, Gabrusiewicz K, Heimberger A. 2013. The controversial role of microglia in 
malignant gliomas. Clin Dev Immunol 2013: 285246. 
Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, 
Wen PY, Stupp R et al. 2015. Glioma. Nature Reviews Disease Primers 1: 15017. 
Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, Weller M, 
Wiendl H. 2003. Expression of the B7-related molecule B7-H1 by glioma cells: a 
potential mechanism of immune paralysis. Cancer Res 63: 7462-7467. 
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung 
WK. 1999. Outcomes and prognostic factors in recurrent glioma patients enrolled 
onto phase II clinical trials. J Clin Oncol 17: 2572-2578. 
Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB. 2010. 
Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro 
Oncol 12: 1113-1125. 
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, 
Jones S, Riggins GJ et al. 2009. IDH1 and IDH2 mutations in gliomas. N Engl J Med 
360: 765-773. 
  43 
 
 
Yang H, Zhang W, Pan H, Feldser HG, Lainez E, Miller C, Leung S, Zhong Z, Zhao H, 
Sweitzer S et al. 2012. SIRT1 activators suppress inflammatory responses through 
promotion of p65 deacetylation and inhibition of NF-κB activity. PLoS One 7: 
e46364. 
Ye J, Liu Z, Wei J, Lu L, Huang Y, Luo L, Xie H. 2013. Protective effect of SIRT1 on 
toxicity of microglial-derived factors induced by LPS to PC12 cells via the p53-
caspase-3-dependent apoptotic pathway. Neurosci Lett 553: 72-77. 
Ying L, Hofseth LJ. 2007. An emerging role for endothelial nitric oxide synthase in chronic 
inflammation and cancer. Cancer Res 67: 1407-1410. 
Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ, Chen J. 2011. Protective effects 
and mechanisms of sirtuins in the nervous system. Prog Neurobiol 95: 373-395. 
Zhang J, Sarkar S, Cua R, Zhou Y, Hader W, Yong VW. 2012. A dialog between glioma and 
microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 
axis. Carcinogenesis 33: 312-319. 
Zhao L, Wang DL, Liu Y, Chen S, Sun FL. 2013. Histone acetyltransferase hMOF promotes 
S phase entry and tumorigenesis in lung cancer. Cell Signal 25: 1689-1698. 
 
